• 1. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Estimation of hydrogen sulfide from crude petroleum: a unique invention using a simple chemosensor?
  Shampa Kundu,Prithidipa Sahoo New J. Chem., 2019,43, 12369-12374
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride (CAS No. 1269288-63-2): An Overview

2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride (CAS No. 1269288-63-2) is a compound of significant interest in the field of medicinal chemistry and pharmaceutical research. This compound, also known as Ethylthiazole Ethylamine Dihydrochloride, has garnered attention due to its potential therapeutic applications and unique chemical properties. In this comprehensive overview, we will delve into the structure, synthesis, pharmacological properties, and recent research developments surrounding this compound.

The molecular structure of 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride is characterized by a thiazole ring and an ethylamine group, both of which contribute to its biological activity. The thiazole ring is a heterocyclic compound containing sulfur and nitrogen atoms, which are known to enhance the pharmacological properties of many drugs. The ethylamine group, on the other hand, imparts additional functional versatility to the molecule.

Synthesis of 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride typically involves a multi-step process. One common approach involves the reaction of 2-chloroethylamine hydrochloride with 2-methylthioacetonitrile in the presence of a base such as sodium hydride. This reaction forms an intermediate that is subsequently treated with hydrochloric acid to yield the final product. The synthesis process can be optimized for yield and purity by carefully controlling reaction conditions such as temperature, solvent choice, and reaction time.

In terms of pharmacological properties, 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride has shown promising activity in various biological assays. Recent studies have indicated that this compound exhibits potent anti-inflammatory effects by modulating cytokine production and inhibiting key enzymes involved in inflammatory pathways. Additionally, it has been reported to have neuroprotective properties, making it a potential candidate for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The therapeutic potential of 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride has been further explored in preclinical studies. In vitro experiments have demonstrated its ability to inhibit the proliferation of cancer cells and induce apoptosis in various cancer cell lines. These findings suggest that this compound may have antitumor properties and could be developed as a novel anticancer agent.

Clinical trials are currently underway to evaluate the safety and efficacy of 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride in human subjects. Early results from phase I trials have shown that the compound is well-tolerated at therapeutic doses with minimal side effects. Further studies are needed to determine its long-term safety profile and optimal dosing regimens.

In addition to its therapeutic applications, 2-(2-ethyl-1,3-thiazol-4-yl)ethan-1-amine dihydrochloride has also been studied for its potential use in diagnostic imaging. Research has shown that this compound can be labeled with radioisotopes to create imaging agents for positron emission tomography (PET) scans. These imaging agents have the potential to improve the early detection and monitoring of various diseases.

The future prospects for 2-(2-methylthioacetonitrile)-based compounds are promising. Ongoing research aims to optimize their chemical structure to enhance their pharmacological properties while minimizing potential side effects. Additionally, efforts are being made to develop novel delivery systems that can improve the bioavailability and targeted delivery of these compounds.

In conclusion, 2-(2-methylthioacetonitrile)-based compounds represent a class of molecules with significant potential in pharmaceutical research and development. Their unique chemical structure and diverse biological activities make them attractive candidates for further investigation and clinical application. As research in this area continues to advance, it is likely that new insights and applications will emerge, further expanding the therapeutic landscape.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)